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ABSTRACT: The cellular and molecular events responsible for reduced fracture healing with aging are
unknown. Cyclooxygenase 2 (COX-2), the inducible regulator of prostaglandin E2 (PGE2) synthesis, is
critical for normal bone repair. A femoral fracture repair model was used in mice at either 7–9 or 52–56 wk of
age, and healing was evaluated by imaging, histology, and gene expression studies. Aging was associated with
a decreased rate of chondrogenesis, decreased bone formation, reduced callus vascularization, delayed re-
modeling, and altered expression of genes involved in repair and remodeling. COX-2 expression in young
mice peaked at 5 days, coinciding with the transition of mesenchymal progenitors to cartilage and the onset of
expression of early cartilage markers. In situ hybridization and immunohistochemistry showed that COX-2
is expressed primarily in early cartilage precursors that co-express col-2. COX-2 expression was reduced by
75% and 65% in fractures from aged mice compared with young mice on days 5 and 7, respectively. Local
administration of an EP4 agonist to the fracture repair site in aged mice enhanced the rate of chondrogenesis
and bone formation to levels observed in young mice, suggesting that the expression of COX-2 during the
early inﬂammatory phase of repair regulates critical subsequent events including chondrogenesis, bone
formation, and remodeling. The ﬁndings suggest that COX-2/EP4 agonists may compensate for deﬁcient
molecular signals that result in the reduced fracture healing associated with aging.
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INTRODUCTION
A
LTHOUGH INCREASED AGE has been a known risk factor
for a decreased rate of fracture healing for >30 yr,
little progress has been made toward understanding the
mechanisms involved.
(1–3) The rate of bone repair is pro-
gressively reduced with aging from the pediatric popula-
tion to the elderly.
(4,5) Delayed healing results in an in-
creased duration of immobilization, increases the risk of
joint stiffness, andis associated with increased morbidity.
(4)
Delayed healing also increases the risk of inadequate frac-
ture alignment.
(6) However, the most signiﬁcant clinical
problem is the development of nonunion. Several studies
have established that aging results in an overall reduction
in union in numerous fractures.
(1–4) This population not
only has an increased risk of fracture caused by reduced
BMD but alsohas reducedfracture healingpotential. Thus,
for any given fracture, the morbidity is greater for the aging
population.
Several studies have evaluated gene expression during
fracture repair and have established differences in the rate
of fracture healing and the pattern of gene expression be-
tween young and aged animals. Stabilized 6-wk-old and 1-
yr-old rat femur fractures had gene expression examined
over a 6-wk period. Whereas fracture union was estab-
lished in young rats 4 wk after fracture, union was consis-
tently absent in aged rats after 6 wk.
(7) Fractures in aged
rats had reduced expression of Indian hedgehog (Ihh) and
BMP-2.
(7) Other studies have established that fractures in
aged mice have delayed expression of bone and cartilage
matrix genes, such as col2, aggrecan, and osteocalcin.
(8) A
recent study of nonstabilized fractures in mice at 4 wk, 6
mo, and 18 mo of age showed decreased fracture callus
volume, delayed maturation of the cartilage callus, and
reduced expression of col2 and colX in aged animals.
(9)
The cyclooxygenases have an important function in
fracture repair with evidence suggesting a critical role
during all stages of healing.
(10–20) COX-2 is transiently
expressed in a number of tissues during periods of inﬂam-
mation.
(21,22) Cyclooxygenase-1 (COX-1) and -2 (COX-2)
catalyze the rate-limiting step in the conversion to arach-
idonic acid to prostaglandin H2 and ultimately to the pro-
duction of prostaglandin E2 (PGE2). PGE2 binds to four
receptor subtypes (EP1–EP4). The EP2 receptor (EP2)
and EP4 receptor (EP4) are Gs-protein–coupled receptors
that are expressed on mesenchymal stem cells, chondrocytes,
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251and osteoblasts.
(21–23) Activation of EP2 and EP4 stimu-
lates the production of cAMP and activation of protein
kinase A (PKA) signaling.
(24) Prior work from our labo-
ratory has shown that stem cells along the periosteum are
essential for bone repair,
(10,25) whereas others have estab-
lished that EP4-mediated signaling is critical for periosteal
bone formation. Delivery of PGE2 using an Alzet pump
along the periosteal surface resulted in abundant periosteal
bone formation in wildtype, EP1
2/2, EP2
2/2, and EP3
2/2
mice. In contrast, EP4
2/2 mice had no bone formation.
(26)
Additionally, PGE2 failed to stimulate the production of
bone nodules in cultures of bone marrow–derived mesen-
chymal stem cells (MSCs) from EP4-deﬁcient mice.
(26) The
development of agonists that target speciﬁc EP receptors
raises the possibility of targeted therapies to potentially
accelerate bone repair.
Previously, we showed that deﬁciency of COX-2 in a
murine model results in a delay in fracture healing.
(19) A
stabilized mouse femur fracture model was used to deter-
mine whether different levels of COX-2 expression could
account for the reduced rate of fracture healing observed
with aging. Our ﬁndings established reduced COX-2 ex-
pression in fractures in aged mice. We further showed that
the delayed fracture healing observed in aged mice could
be rescued with local delivery of an EP4 selective agonist.
The ﬁndings establish a role for COX-2 expression in the
delayed fracture healing observed with aging.
MATERIALS AND METHODS
Experimental animals
All animal studies were done in accordance and with
approval of the University Committee on Animal Re-
sources. Fifty-two-week-old female C57BL/6J mice were
obtained from the National Institutes on Aging (Bethesda,
MD, USA). C57BL/6J, 7- to 9-wk female mice were pro-
cured from Jackson Laboratories (Bar Harbor, ME, USA).
Stock aged animals were rederived from Jackson Labora-
tory breeders in 1990, 1998, and 2005. This routine practice
by the NIA was done to eliminate genetic drift that could
have occurred between the two populations of mice.
Femur fracture model
Mice received anesthesia using ketamine and xylazine.
The skin and underlying soft tissues over the left knee was
incised lateral to the patellar tendon. The tendon was dis-
placed medially, and a small hole was drilled into the distal
femur using a 26-gauge needle. A stylus pin from a 25G
Quincke Type spinal needle (BD Medical Systems,
Franklin Lakes, NJ, USA) was inserted into the intra-
medullary canal and clipped. The wound was sutured
closed. Fractures were created using a three-point bending
Einhorn device as previously described.
(27) Mice were
given six subcutaneous injections of 2 mg/kg Buprenor-
phine (Abbot Laboratories, Abbott Park, IL, USA) every
12 h to control pain. A Faxitron system (Faxitron X-ray,
Wheeling, IL, USA) was used to take X-ray images at the
time of surgery, 1-week intervals, and at the time of death.
Histology and analysis
Mice were killed at 3, 5, 7, 10, 14, 18, 21, 25, 30, or 35 days
after fracture. A normal mid-diaphysis femoral bone seg-
mentwasusedasanonfracturedday0control.Femurswere
disarticulated from the hip and trimmed to remove excess
muscle and skin. Specimens were stored in 10% neutral
bufferedformalinfor2days.Thetissueswereinﬁltratedand
embedded in parafﬁn. Alcian blue and orange G along with
TRACP staining was done as previously described.
(19,20,28)
Histomorphometric analysis (n = 4 animals per group) was
done using a standardized eyepiece grid to measure tissue
areas within the fracture callus. Samples were cut at four
levels spanning ;120 mm through the callus, with 30 mm
between each level. Each cross-hatch was categorized as
not callus (not counted), callus (quantiﬁed), and a speciﬁc
tissue type. A total area of the external callus and areas of
individual tissue types such as new bone (mineralized tis-
sue), total cartilage, immature proliferative cartilage, hy-
pertrophic cartilage, and mesenchyme were quantiﬁed.
Bone was deﬁned as areas of new woven bone. Cartilage
was deﬁned as tissues staining blue for proteoglycan. Hy-
pertrophic cartilage was clearly deﬁned by cellular mor-
phology, and other nonhypertrophic areas of cartilage were
considered immature cartilage. Finally, mesenchyme was
deﬁned as areas containing spindle-shaped ﬁbroblasts with-
out Alcian blue staining. Cortical bone was excluded from
the histomorphometric analysis. The target tissue area was
divided over the area of the external callus.
In the rescue experiment, aged mice were treated with
either vehicle or a nonprostanoid EP4 selective agonist,
CP432 (Pﬁzer, Groton, CT, USA). CP734432 (CP73) was
freshly prepared in normal saline containing 3% ethanol.
CP73 (100 ml) was injected at the fracture site twice daily
for a total daily dose of 20 mg/kg/d.
Quantitative real-time PCR
The fracture callus and 1 mm of normal bone margin was
carefully excised using a scalpel. These samples were frozen
in liquid N2, pulverized using a nitrogen-cooled mortar and
pestle apparatus (Bel-Art, Scienceware, Pequannock, NJ,
USA), and puriﬁed for total RNA using the TRIzol system
(Invitrogen, Carlsbad, CA, USA).
(29) The concentration of
stock RNA was determined using a spectrophotometer.
cDNA was synthesized from 0.5 mgo fR N Ap e rc a l l u su s i n g
a commercial ﬁrst-strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA, USA). cDNA from n = 4 mice from each
group was pooled. RT-PCR analyses were performed using
murinespeciﬁc primersfor col2a1, colX,osteocalcin,BMP-2
and -4, COX-2, RANKL, and OPG expression (see Table
1 for speciﬁc sequences). The col2a1 and colX mRNAs
encode for the collagen matrix proteins type II collagen and
type X collagen, respectively. col2a1 is maximally expressed
during chondrocyte proliferation and colX peaks during
terminal differentiation of chondrocytes. Osteocalcin is ex-
pressed in fully mature osteoblasts. BMP-2 and BMP-4 are
genes that encode for two subtypes of the bone morphoge-
netic proteins that are involved chondrogenesis and bone
formation.
(30) RANKL stimulates osteoclastmaturation and
bone remodeling, an important phase of fracture repair.
(20)
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creted decoy receptor for RANKL, which serves to regulate
osteoclastogenesis.
(20) qPCR reaction was performed us-
ing SyberGreen (ABgene, Rochester, NY, USA) in a
RotorGene real-time PCR machine (Corbett Research,
Carlsbad, CA, USA). All genes were compared with a
standard b-actin control. Data were assessed quantitatively
using two-way analysis of covariance comparing relative
levels of transcript expression as a function of time and age.
Immunohistochemistry
Immunohistochemistry was done as previously de-
scribed.
(31) Sections were deparafﬁnized using xylene and
rehydrated using graded alcohols. The endogenous per-
oxidase was quenched using 3% hydrogen peroxide for 20
min. Nonspeciﬁc binding epitopes were blocked using 1:20
normal goat serum. Slides were incubated at 48C overnight
with a 1:200 dilution of mouse primary COX-2 antibody
(Cayman Chemical, Ann Arbor, MI, USA). Sections were
rewarmed, rinsed in PBS, incubated with a 1:200 goat anti-
rabbit secondary antibody, rinsed again in PBS, and ﬁnally
incubated with a 1:250 horseradish peroxidase (HRP)
streptavidin for 30 min. Sections were counterstained with
hematoxylin and rinsed. The RANKL goat anti-mouse
antibody (Santa Cruz Biotechnologies, Santa Cruz, CA,
USA) incubation was done using a 1:20 dilution factor. The
immunohistochemical data were qualitatively assessed.
In situ hybridization
Femursprepared for in situhybridization wereﬁxed in 4%
paraformaldehyde by intracardiac injection and immersion
at 48C for 3 days. All samples were decalciﬁed in 10%
EDTA for 21 days before sectioning. The mouse legs were
dissected by disarticulating the femoral head from the hip
and immediately immersed in ﬁxative. Excess muscle and
pins were carefully removed. Tissues were placed in parafﬁn
and sectioned. In situ hybridization was performed using the
mRNAlocator kit (Ambion, Foster City, CA, USA). Pro-
teinase K digestion was done at 378C for 13 min, and the
hybridization reaction was carried out at 558C overnight.
Plasmids for the
33P-UTP labeled riboprobes were provided
by Jill Helms (col2, colX,a n dosteocalcin)
(30) and Adam
Sapirstein (COX-2).
(32) Sections were observed using both
light- and dark-ﬁeld microscopy and assessed qualitatively.
mCT
On death, femurs were disarticulated from the hip and
ﬁxed in 10% neutral buffered formalin (NBF). For vascular
perfusion studies, mice were killed and given serial intracar-
diac injections of heparinized saline, 10% NBF, and a lead
chromate microﬁl perfusion reagent (Flow Tech, Carver, MA,
USA). The wholemiceweresoakedin 10%NBF overnight at
48C. The fractured limbs were disarticulated at the hip, and
excess soft tissue was removed. Calluses were further ﬁxed in
NBF for 2 additional days, and decalciﬁed in 10% EDTA for
21 days. The samples were scanned twice, before and after
decalciﬁcation, in a VivaCT Scanner (Scanco Medical AG,
Bassersdorf, Switzerland) at high resolution with a 12.5-mm
voxel size. An integration time of 300 ms, a current of 145 mA,
and an energy setting of 55 kV was used. The threshold was
chosen using 2D evaluation of several slices in the transverse
anatomic plane so that mineralized callus and vascular con-
trast reagent were identiﬁed but surrounding soft tissue was
excluded. An average threshold of 250 was optimal and used
uniformly for all samples. Next, each sample was contoured
around the external callus and along the edge of the cortical
bone. All mineralized tissues above threshold between these
two boundaries were included. Thus, external soft tissues and
cortical bone including the marrow cavity were excluded.
Contouring of images was done every 20 axial slices proxi-
mally to distally until the callus was not visible. Because all
the soft tissue was removed, it was possible to detect the
entire callus volume by lowering the threshold. The volume
of the mineralized tissue or vascular bed was divided by the
volume of the whole external callus. We used an n=5sa m p l e
size for each group. Data sets were examined using statistical
assessments including ANOVA.
Statistics
Statistical analysis was performed as previously de-
scribed.
(19)Theresultsweredescribedasmean±SE.Statis-
tical signiﬁcance was determined using two-way ANOVA
and Student’s t-tests. These tests determined signiﬁcance
between young/old mice and the values at different time
points. p < 0.05 was considered signiﬁcant. Data analysis
was performed using GraphPad Prism version 5.0
(GraphPad Software, San Diego, CA, USA).
RESULTS
Fractures in aged mice have delayed radiographic
healing, decreased bone formation, vascularization,
and remodeling
Radiographs at various time points during fracture heal-
ing were obtained(Fig. 1A). Calciﬁed callusand evidenceof
TABLE 1. LIST OF OLIGONUCLEOTIDE PRIMER SEQUENCES
FOR REAL-TIME PCR
Gene Sequence
b-actin 59-AGATGTGGATCAGCAAGCAG-39
59-GCGCAAGTTAGGTTTTGTCA-39
COX-2 59-CACAGCCTACCAAAACAGCCA-39
59-GCTCAGTTGAACGCCTTTTGA-39
Col2a1 59-ACTGGTAAGTGGGGCAAGAC-39
59-CCACACCAAATTCCTGTTCA-39
ColX 59-ACCCCAAGGACCTAAAGGAA-39
59-CCCCAGGATACCCTGTTTTT-39
Osteocalcin 59-CTTGGTGCACACCTAGCAGA-39
59-CTCCCTCATGTGTTGTCCCT-39
BMP-2 59-TGGAAGTGGCCCATTTAGAG-39
59-GCTTTTCTCGTTTGTGGAGC-39
BMP-4 59-TGAGCCTTTCCAGCAAGTTT-39
59-CTTCCCGGTCTCAGGTATCA239
RANKL 59-CACCATCAGCTGAAGATAGT-39
59-CCAAGATCTCTAACATGACG-39
OPG 59-AGTCCGTGAAGCAGGAGTG-39
59-CCATCTGGACATTTTTTGCAAA-39
COX-2 EXPRESSION IS REDUCED IN AGED FRACTURES 253bone union were observed in the fractures of young mice at
days 10 and 14, respectively, but were delayed in fractures
from aged mice until 14 and 18 days after fracture (Fig.
1A). The radiographic delay in fracture healing was con-
sistently observed (Fig. 1B; n = 4 young and n = 4 aged
mice). Remodeling also occurred earlier in young mice
(Fig. 1A). By 25 days after fracture, clear evidence of re-
modeling was observed, and radiographic remodeling was
nearly complete by 35 days. In fractures from aged mice,
limited evidence of radiographic remodeling was observed
35 days after fracture.
mCT was performed on mice harvested at 10, 14, and 18
days after fracture. Previously it has been shown that vas-
cularization is a sensitive marker of the completion of en-
dochondral bone formation and is important in the pro-
gression of fracture repair.
(33–35) For this reason, the
fractures were perfused with lead chromate microﬁl so that
the vascularization within the callus could be determined in
fractures in young and aged mice. mCT showed delayed
bone formation, fracture union, and vascularization in
fractures from aged mice compared with fractures from
young mice. Similar to the data observed in radiographs,
fracture healing was complete in young mice by 14 days
after fracture. In contrast, healing wasdelayed until 18 days
in aged fractures, and callus vascularization was delayed
(Figs. 1C and 1D). Quantitative assessment of these pa-
rameters showed that mineralization was increased in
fractures in young mice compared with aged mice by 1.9-
and 2-fold at 10 and 14 days, respectively (Fig. 1E). How-
ever, mineralization was similar by 18 days after fracture.
Similarly, vascularization was increased 1.7- and 2.0-fold in
fractures from young compared with aged mice at 10
and 14 days but reached equivalent values by 18 days after
fracture (Fig. 1F). These ﬁndings suggest a delay in the
completion of endochondral ossiﬁcation in aging fractures.
Fractures in aged mice have delayed chondrogenesis
and completion of endochondral ossiﬁcation,
impaired bone remodeling, and altered
gene expression
Histology sections of the fractures conﬁrmed a delay in
fracture healing and remodeling in aged mice (Fig. 2).
Whereas cartilage formation was observed in both young
FIG. 1. Aged mice have a radiographic de-
lay in fracture healing. Serial radiographs of
representative young and aged mice at vari-
ous times after fracture. Young mice showed
evidence of callus mineralization by day 10,
which was delayed to day 14 in aged mice
(A, *). By day 14 in young mice and day 18 in
aged mice, the callus showed union (black
arrows). Remodeling was delayed in aged
mice compared with young mice (A, white
arrows). The delay in fracture repair was
consistently observed in day 14 fractures (n =
4) (B). Fractures were harvested, and high-
resolution mCT scans were performed on
young (n = 5) and aged (n = 5) mice. For
vascular analysis, mice were perfused with a
lead chromate microﬁl contrast reagent be-
fore decalciﬁcation. Representative scans are
shown for days 10, 14, and 18 for calciﬁed
callus (C) and vascularization (D) for young
and aged mice, respectively. Mean calculated
mineral (E) and vascular (F) volumes were
obtained. Mineral volume analysis showed
lower mineral accretion in aged mice, par-
ticularly on days 10 and 14 (C and E). On
days 10 and 14, aged mice have a signiﬁcant
reduction in the proportion of blood vessels
in their calluses compared with young mice
(D and F). Statistical comparisons were per-
formed using ANOVA and are denoted by
symbols: *p < 0.05 and **p < 0.005.
254 NAIK ET AL.and aged mice on day 7, cartilage undergoes more rapid
maturation and endochondral bone formation is complete
by day 14 in young mice. In contrast, cartilage is present in
aged fractures at 14 days and areas of cartilage remains
through 18 days. Histomorphometry was performed at
each time point to quantify the amount of mesenchyme,
cartilage, and bone present in the sections (Figs. 2M–2O).
Fractures in aged mice had reduced callus formation early
and delayed chondrogenesis, bone formation, and remod-
eling (Figs. 2M–2O). Total bone area was signiﬁcantly
higher in the fractures of young mice on days 7, 10, and
14 but was lower at days 25 and 30 after remodeling of the
fracture. In contrast, aged animals continue to have a net
increase in bone area until day 25 (Fig. 2M). In young
animals, peak cartilage area is observed at day 10 and is
almost entirely replaced by bone by day 14. However, in
aged animals, abundant cartilage persists at day 14. Frac-
tures in both young and aged mice have calluses almost
entirely composed of bone by day 21 (Fig. 2N). Delayed
bone formation and chondrogenesis result in delayed peak
total callus area and remodeling in aged animals (Fig. 2O).
Histology showed more rapid remodeling in fractures in
young mice (Fig. 2). By 18 days, young mice have evidence
of extensive remodeling, and at 25 days, most of the initial
woven bone within the callus has been remodeled. By 35
days, the fractures in young mice have essentially under-
gone complete remodeling and the femur is achieving a
morphology similar to the nonfractured bone. These events
are markedly delayed in the fracture callus from aged mice.
Extensive remodeling is not observed until 25 days, and at
35 days, fracture callus in aged mice remains enlarged and
contains areas of woven bone (Fig. 2).
Expression of genes involved in matrix accumulation,
bone formation, and remodeling is altered in
fractures from aged mice
Total RNA was harvested from fractures at various
times between 3 and 35 days to examine molecular events
underlying the delayed healing observed in aged mice. In
the fractures from young mice, col2a1 appeared earlier,
and peak levels were observed by days 7–10 compared with
maximal expression at day 10 in aged mice (Fig. 3A).
Similarly, maximal expression of the chondrocyte matu-
ration marker, colX, occurred from days 7 to 10 in fractures
from young mice, whereas aged mice had maximal ex-
pression occurring at day 10. Maximal col2a1 and colX
expressions were signiﬁcantly higher in fractures from
young mice (Fig. 3B), consistent with the increase in car-
tilage observed in young mice by histomorphometry.
Moreover, both col2a1 and colX expressions disappear
in young mice by day 14, signifying completion of the
endochondral phase of fracture repair, whereas cartilage
matrix gene expression persists until day 21 in aged mice.
FIG. 1. (Continued).
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Fig. 1 is 4/CEarly and late peaks of osteocalcin expression were ob-
served (Fig. 3D). An early minor peak occurred at day 3
when initial intramembranous ossiﬁcation occurs along the
periosteal bone surface. Osteocalcin levels were slightly
higher in fractures from aged mice at this early peak com-
pared with those observed in young mice. However, by 5
through 10 days, osteocalcin levels were signiﬁcantly in-
creased in fractures from young mice. Peak expressions
were reached in both young (14–18 days) and aged mice (14
days),and althoughhigherinyoungmice,the difference was
not statistically signiﬁcant. At 21 days, osteocalcin expres-
sion was elevated in fractures from aged mice compared
with fractures from young mice. Altogether, the osteocalcin
expression levels are consistent with a more robust early
formation of bone in fractures from young mice, consistent
with their earlier completion of endochondral ossiﬁcation
Expressions of BMP-2 and BMP-4 were examined in the
fracture calluses, and distinct temporal patterns of ex-
pression were observed (Figs. 3E and 3F). In fractures
harvested from young mice BMP-2, expression was ele-
vated early during the endochondral phase of fracture re-
pair, with peak expressions present between 5 and 10 days,
with a subsequent decrease during the bone formation
phase of repair. In contrast, BMP-4 expression was highest
at 14 days, corresponding to the peak of osteocalcin ex-
pression and bone formation.
BMP-2 and BMP-4 had an overlapping pattern of ex-
pression in aged mice (Figs. 3E and 3F). BMP-2 expression
was maximal in aging fractures between 10 and 18 days
compared with 5–10 days in young mice. Similarly, BMP-4
expression was elevated between 10 and 18 days in contrast
to the single peak of expression that occurred in young
mice at 14 days. This is consistent with less distinct cartilage
and bone formation phases of fracture healing observed in
the aged mice.
Finally, consistent with the diminished bone remodeling
observed on radiographs and histological sections, the
pattern of RANKL and OPG expressions was markedly
altered in fractures from aged mice (Figs. 3G and 3H).
Peak RANKL expression occurs surprisingly early in the
process of fracture repair and is observed at the onset
of chondrogenesis. Young mice had an abrupt peak in
FIG. 2. Fractures in agedmice havedelayed
cartilage and bone formation. Histology sec-
tions were prepared from young and aged
mice harvested at various times after fracture
(A–L). By day 10, calluses were composed of
abundant mature cartilage in young mice
compared with largely immature cartilage in
aged mice. By day 14, most callus tissue
consisted of new bone in young animals,
whereas aged animals showed a persistence
of cartilage and delayed completion of en-
dochondral ossiﬁcation. On days 18, 25, and
35, young mice had more advanced remod-
eling compared with aged animals. Histo-
morphometric analysis of total callus, bone,
and cartilage areas were completed in n =4
young and n = 4 aged mice, respectively, with
three levels analyzed per sample. Histomor-
phometry showed delayed formation of car-
tilage, bone and total callus area in aged mice
(M–O). Statistical comparisons were per-
formed using ANOVA and signiﬁcant dif-
ferences are denoted by symbols: *p < 0.05
and **p < 0.005.
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Fig. 2 is 4/CRANKL expression at 5 days with a gradual decline to
basal levels by 21 days, suggesting that the induction of
osteoclastogenesis and remodeling is one of the early mo-
lecular events to occur in fracture repair. A similar abrupt
peak in OPG expression was observed in fractures in
young mice but occurred at day 7 after fracture and thus
immediately followed the induction in RANKL. In con-
trast, fractures in aged mice showed a less brisk but more
prolonged elevation of RANKL from days 5 to 18 after
fracture. Interestingly OPG gene expression pattern mir-
rored that observed with RANKL, but with peak levels
occurring between 7 days and at 21 days in fractures from
aged mice. These ﬁndings show that RANKL and OPG
expressions are temporally linked, with maximal RANKL
expression occurring well before the peak of bone re-
modeling and immediately followed by an increase in the
expression of the decoy receptor, OPG.
COX-2 is altered in fractures in aged mice
COX-2 has previously been shown to be an important
anabolic agent for fracture repair.
(18,19,36) In normal
bone harvested from the femoral shaft, basal levels of
COX-2 expression was similar in young and aged bone
tissue (Supplemental Fig. 1). After fracture, COX-2
expression was induced early and preceded the onset of
chondrogenesis (Fig. 3H). In fractures from young
mice, COX-2 was increased by 3 days and had a sharp
peak of maximal expression at 5 days. COX-2 levels
declined rapidly and returned toward baseline levels by
10–14 days. In fractures from aged mice, the magnitude
COX-2 induction was markedly less and the peak ex-
pression was less distinct so that a much lower level of
maximal COX-2 expression was sustained between 5
and 10 days.
FIG. 3. Fracture in aged mice have altered patterns of gene expression during the chondrogenesis, bone formation, and remodeling
phases of repair. Total RNA was harvested and pooled from n = 4 young and aged mice at various points. Real-time RT-PCR was
performed and normalized to b-actin expression. Values from young mice are shown in the white bars and aged mice in the black bars.
The bars at the top of each ﬁgure denote the period of time in which maximal expression of each gene occurred in the fractures from both
young (white bar) and aged (black bar) mice. Peak expression of col2a1, COX-2, RANKL, and OPG occur in fractures in young mice
during the chondrogenic phase of fracture healing between days 0 and 7 (A, F, G, and H). ColX and BMP-2 are maximal at day 10 during
the peak of endochondral bone formation (B and D). Finally, osteocalcin and bmp-4 gene expression (C and E) are maximal at day 14,
consistent with the peak of primary bone formation on the cartilage template. In contrast, fractures have mice have an altered pattern of
gene expressions. COX-2 gene expression was diminished on days 3, 5, and 7 during the phase of chondrogenesis (H). Other genes were
delayed, had reduced or delayed maximal expression, or had a broader duration of expression. Statistical comparisons were performed
usingANOVAand signiﬁcance denotedby symbols:*p <0.05and **p <0.005. Peakexpressionperiodsare denotedby the barsatthe top
of the ﬁgure. The maximal value measured in young and old mice for each gene is statistically different (p < 0.05; A, B, E, F, and H) in all
cases except for panels in which ‘‘ns’’ appears with the bars (C, D, and G).
COX-2 EXPRESSION IS REDUCED IN AGED FRACTURES 257The ﬁnding that maximal COX-2 expression occurs at
the onset of chondrogenesis suggests a connection with this
process. In situ hybridization and immunohistochemistry
were performed to determine whether COX-2 and col2a1
were co-expressed in a chondroprogenitor population. Fe-
mur sections harvested from young mice between 3 and
10 days after fracture were hybridized to antisense probes
speciﬁc for COX-2 and col2a1, and X-ray ﬁlm based auto-
radiography was performed (Fig. 4A). The autoradiograph
shows abundant expression of col2a1 in fracture callus and
in the distal femoral growth plate. Maximal expression
occurred between 7 and 10 days, but lower levels of ex-
pression were observed at 3 and 5 days after fracture.
COX-2 hybridization overlapped with areas of col2a1 ex-
pression (Fig. 4A). However, COX-2 maximal expression
occurred at the earlier times (3–7 days) when fracture callus
is composed of a less differentiated chondroprogenitor cell
population.
To determine the cell populations expressing COX-2,
emulsion-based autoradiography was performed in day 5
fractures (Fig. 4B). Both COX-2 and col2a1 expression was
co-localized in populations of chondroprogenitor cells that
were transitioning from a ﬂat mesenchymal cell morphol-
ogy to a rounded chondrocyte in the process of becoming
embedded within the matrix. Thus, chondroprogenitors
and early chondrocytes are the major source of COX-2
expression in early fracture repair.
To conﬁrm the ﬁndings and to examine the relative ex-
pression of COX-2 in young and aged mice, immunohis-
tochemical staining for COX-2 was performed on fractures
from young and aged mice between 5 and 14 days (Fig. 5).
In fractures from young mice, strong COX-2 staining was
observed inmesenchymal cells andimmature chondrocytes
at 5 and 7 days after fracture. By 10 days, COX-2 staining
was minimal in cartilage, and at this point, localized pri-
marily to the periosteum and osteoblast population. A
different pattern of expression was observed in fractures
from aged mice; COX-2 expression was relatively less at
5 and 7 days but persisted in cartilage through 14 days,
consistent with the altered gene expression pattern ob-
served in fractures from aged mice.
COX-2 and RANKL are co-expressed in
chondroprogenitor cells in fracture callus
It has previously been established that PGE2 induces the
expression of RANKL, a factor essential for the induction
of osteoclasts.
(20) Immunohistochemistry was performed
in 7-day fracture calluses from young mice to examine
expression of RANKL and COX-2 because both genes are
highly expressed in fractures at that time (Figs. 3G, 3H, and
6A). Fracture sections stained with anti-RANKL and anti-
COX-2 show an essentially identical localization of these
key signals. Both proteins are localized in immature
chondrocytes, osteoblasts, and vascular endothelium but
not to hypertrophic chondrocytes.
To evaluate whether the differences in RANKL ex-
pression in fracture calluses of young and aged mice was
associated with altered osteoclast-mediated bone resorp-
tion, TRACP staining was performed on callus tissues be-
tween 7 and 21 days and qualitatively assessed (Fig. 6). In
young mice, TRACP
+ osteoclasts were evident by day 7
along the periosteal surface. Abundant remodeling of
woven bone was apparent at day 14 throughout the callus.
In contrast, the appearance of TRACP
+ osteoclasts was
delayed until 10 days in fractures from aged mice and was
not extensive in the callus tissue until 21 days after fracture.
Local delivery of an EP4R agonist (CP73) rescues the
delayed fracture healing phenotype in aged mice
The radiographic, histological, and molecular charac-
terization of fractures in aged mice suggests that an early
disruption in the progression of healing persists and results
in a sustained delay of the entire reparative process. Be-
cause COX-2 is an important early anabolic gene and is
markedly reduced in aged fractures, we examined whether
the local delivery of the EP4 agonist CP73 could com-
pensate for the delayed fracture repair that occurs in aged
mice. CP73 (10 mg/kg/injection) or vehicle was injected
into the fractures of aged mice twice daily between 1 and 21
days after fracture and compared with fractures in young
mice that received vehicle injections. Tissues harvested
after 14 days showed healing in young mice with minimal
remaining cartilage and abundant bone formation (Fig.
7A). Fractures in aged mice treated with CP73 had reduced
cartilage and increased bone compared with vehicle-trea-
ted control fractures (Fig. 7A). Histomorphometry showed
that fractures in vehicle-treated young mice were com-
posed of 85% bone, 13% cartilage consisting of 1% im-
mature cartilage, and only 2% undifferentiated mesen-
chyme. In contrast, fractures in vehicle-treated aged mice
were composed of 64% bone, 26% cartilage (5% imma-
ture), and 8% undifferentiated mesenchyme. Addition of
CP73 increased bone formation to 76% and reduced the
composition of cartilage to 20% (1% immature) and 3%
undifferentiated mesenchyme (Fig. 7B; p < 0.05). Consis-
tent with data shown in Fig. 2, day 14 vehicle-treated
fractures in aged mice have increased callus area compared
with vehicle-treated young mice (Fig. 7C). Whereas callus
area was similar in vehicle and CP73-treated aged mice,
CP73 signiﬁcantly increased bone area, consistent with the
more rapid completion of endochondral ossiﬁcation (Fig.
7D). The total bone area was similar to that observed in the
vehicle-treated young mice. Thus, CP73 accelerates the
endochondral phase of bone repair in aged mice and results
in a pattern of healing that mimics fracture healing in
young mice.
In 21-day fractures, untreated (Fig. 2) and vehicle-treated
(Fig. 7) fracture calluses in young and aged mice have
similar total callus and bone areas (Figs. 2 and 7). CP73
treatment for 21 days resulted in signiﬁcantly enhanced
callus size and bone formation in aged mice compared with
the vehicle-treated young and aged mice with fractures.
These ﬁndings suggest that, in the later phases of fracture
repair, CP73 may have additional effects on the osteoblast
population that results in increased total bone formation
and callus area. Thus, in addition to its early effects of
accelerating callus maturation, CP73 also results in in-
creased in callus size and bone formation at later times.
258 NAIK ET AL.FIG. 4. Cox-2 mRNA is expressed in chon-
droprogenitor cells in healing fractures. In
situ hybridization was performed on fractures
obtained from young mice between 3 and 10
days after fracture using murine speciﬁc sense
and antisense riboprobes for COX-2 and
col2a1. Detection was with Kodak Biomax
MR X-ray ﬁlm. COX-2 expression occurs in
regions where early chondrocyte precursors
express col2a1. COX-2 expression subse-
quently declines as chondrocytes mature
(Figure 5A). Microscopic expression was de-
termined in histological sections of day 5
fracture callus and conﬁrms the co-expression
of COX-2 and col2a1 in early chondro-
progenitor cell populations (Figure 5B). S-10d
represents use of the sense probe on day
10 tissue sections, which acts as a negative
control.
FIG. 5. COX-2 protein localizes to chon-
droprogenitors and the early chondrocyte
population. Immunohistochemical staining
for COX-2 was performed on fracture cal-
luses from young (left; Y) and aged mice
(right; A) between 5 and 14 days. Consistent
with mRNA data, COX-2 protein was most
abundantly expressed in chondroprogenitors.
In young mice at day 10, the COX-2 signal
almost completely disappears from cartilage
and is limited to the periosteum and osteo-
blasts. Aged mice have fewer cartilage cells
staining positive on days 5 and 7 but have
persistent expression in cartilage through
days 10 and 14.
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Figs. 4, 5 is 4/CDISCUSSION
During fracture healing, there is a sequential series of
highly linked events that include mesenchymal prolifera-
tion, chondrogenesis, chondrocyte maturation and termi-
nal differentiation, vascularization, primary bone forma-
tion, and remodeling.
(37) Because these events are tightly
linked, cellular and molecular alterations that occur early
during the healing response may result in an alteration in
the timing of subsequent events. Thus, the early cell, tissue,
and molecular events that occur immediately after bone
injury have particular importance.
The phenotype of fracture repair in aged mice is con-
sistent with altered early gene expression. Compared with
young mice, aged mice have delayed formation of callus
and chondrogenesis, suggesting a decrease in the rate of
proliferation and differentiation of mesenchymal chon-
droprogenitors. Maximal expression of col2a1 occurred
later, and gene expression persisted for a longer duration.
ColX, a marker of mature chondrocytes,
(38,39) was maximal
at 7–10 days in fractures from young mice and at day 10 in
fractures at aged mice. Furthermore, fractures in aged mice
had reduced peak levels of colX expression and expression
persisted through 18 days, showing failure to efﬁciently
complete endochondral bone formation. Mature, calciﬁed
cartilage acts as a template for bone formation and re-
modeling. Consistent with the delay and prolongation of
the cartilage phase of fracture repair, osteocalcin gene peak
expression was reduced and expression also persisted in
aged callus. Finally, vascularization and fracture union
were delayed and the rate of remodeling was reduced in
aged fractures. These ﬁndings are consistent with previous
descriptions of delayed fracture healing in older mice and
rats.
(7,40–42)
COX-2 has been shown to be a critical regulator of bone
repair in multiple animal models.
(19,20,43–46) COX-2 ex-
pression is rapidly induced in fractures, consistent with our
observation of expression in 3 day calluses, with peak ex-
pression by 5 days in young mice. COX-2–deﬁcient mice
have a fracture healing phenotype that is similar to aged
mice, including a slower rate of chondrogenesis, chondro-
cyte maturation, delayed vascularization, and reduced
bone formation. In COX-2
2/2 mouse fractures, there is
persistence of undifferentiated mesenchyme, suggesting
that COX-2 is necessary for normal bone and cartilage
differentiation in healing tissues.
(19)
In vitro studies have conﬁrmed that COX-2 and its me-
tabolite, PGE2, enhance the differentiation of MSCs into
both cartilage and bone.
(19,23,47,48) Addition of PGE2 to limb
bud MSCs in high-density cultures enhances chondrogene-
sis.
(23) This has been observed in primary avian and murine
cultures and mesenchymal cell lines and involves signaling
through PKA.
(23,47,48) Similarly, PGE2 has been shown to
stimulate osteoblast differentiation.
(19,26) Bone marrow
MSC cultures isolated from COX-2
2/2 mice have reduced
osteoblast differentiation. However, this can be compen-
sated by the addition of PGE2 to the cultures, suggesting that
PGE2 is a key metabolite in osteoblast differentiation.
(19)
Whereas a role for COX-2 in bone repair has been
extensively described, the cell populations responsible
for COX-2 expression in fracture callus have not been
deﬁned. In situ hybridization experiments showed co-
localization of COX-2 and col2a1 in the early chondropro-
genitor population. Morphologically, these were ﬂattened
FIG. 6. Fractures in aged mice have delayed
osteoclast formation. High-power images,
320 and 340, show immunostaining using
anti-COX-2 and anti-RANKL antibodies in
chondroprogenitors and immature chondro-
cytesat7daysafterfracture.Endothelial cells
(arrow) also stained for COX-2 and RANKL
(A). Tissues were harvested from young and
aged mice at 7, 10, 14, or 21 days after frac-
ture, and sections were stained for TRACP
(B–I). The sections from young mice show
TRACP
+ osteoclasts by day 7 along the per-
iosteal surface (B). Osteoclasts increase
through day 14 when the entire callus is in-
terspersed with TRACP
+ osteoclasts (F). By
day 21, remodeling is advanced, and the
number of osteoclasts is reduced (H). In
contrast, osteoclasts do not appear until day
10 in fractures from aged mice, and resorp-
tion area appears maximal at 21 days (C, E,
G, and I).
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Fig. 6 is 4/Cﬁbroblastic-appearing mesenchymal progenitors in the
process of becoming embedded within a chondroid matrix.
COX-2 expression was also present in immature chon-
drocytes but was absent in cells with a hypertrophic phe-
notype. Interestingly, COX-2 expression is absent in the
growth plate, consistent with lack of a developmental
phenotype in COX-2
2/2 mice. Thus, the expression of
COX-2 seems to be unique to reparative cartilage. COX-2
expression was also present in the osteoblast population,
although gene expression studies suggest that the highest
levels of expression were associated with the initial carti-
lage phases of endochondral bone repair. Whereas prior
work has established that osteoblasts express COX-2, these
are the ﬁrst experiments to show that cartilage is a major
source of COX-2 during fracture repair. COX-2 expression
was reduced in the fracture callus of aged mice, suggesting
that the delayed healing in these mice may be caused by a
functional decrease in this enzyme.
PGE-2 is the major metabolite of COX-2 in most tissues
and activates one of four receptors, EP1, EP2, EP3, and
EP4, thatcollectively are associatedwith the protein kinase
C (PKC) and PKA signaling pathways. Numerous genes
have been shown to be activated by PGE2, including BMP-
2 and RANKL, two critical factors in bone repair.
(20,49–51)
In young fractures, BMP-2 and RANKL both have peak
expression during the early cartilage period of fracture
repair and are expressed in phase with COX-2. EP2 and
EP4 agonists have been shown to enhance bone formation
in several bone repair models and may have anabolic ef-
fects when combined with BMP-2 therapy.
(24,26,52–56) In an
ectopic bone formation model, BMP-2 and selective EP4
agonists had a synergistic effect.
(56) In rat growth plate
chondrocytes, combined activation of EP2 and EP4 re-
ceptors resulted in enhanced proliferation and induction of
col2a1 expression.
(57) The observation that both anabolic
and remodeling genes have peak expressions during the
early chondrogenic period of fracture repair further sup-
ports the notion that initial cellular and molecular events
drive the overall repair process.
Aged mice have reduced and temporally prolonged ex-
pressions of both BMP-2 and RANKL. BMP-2 is regulated
by COX-2 and PGE2 through EP4.
(49) Undifferentiated
FIG. 7. Administration of an EP4 agonist to
fractures in aged mice accelerates fracture
repair and increase bone formation. Fractures
in young mice were injected with vehicle (100
ml twice per day), whereas fractures in aged
mice received injection of either vehicle or a
selective EP4 agonist (CP73; 20 mg/kg/d).
Mice (n = 4 per group) were harvested 14 and
21 days after fracture, and tissues were pre-
pared for histology. Representative sections
from day 14 are shown in A. Histomor-
phometry was used to measure the relative
populations of undifferentiated mesenchyme,
immature cartilage, hypertrophic cartilage,
total cartilage, and new bone at day 14 (B).
Total callus and bone area was measured on
days 14 and 21 (mm
2) (C and D). CP73 ac-
celerated the completion of endochondral
bone formation and resulted in reduced car-
tilage and increased bone formation com-
pared with the vehicle-treated aged fractures.
The anabolic effects of CP73 on bone for-
mation persisted to day 21 in aged animals.
These changes compensated for the age-re-
lated effects on fracture healing (B–D). Sta-
tistical comparisons were performed using
ANOVA, and signiﬁcance is denoted by
symbols: *p < 0.05 and **p < 0.005.
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Fig. 7 is 4/Chuman MSCs constitutively express more COX-2, PGE2,
and BMP-2 than mature osteoblasts.
(49) When treated with
selectiveCOX-2 andEP4 inhibitors,the induction of BMP-
2 in these cells was suppressed.
(49) Similarly RANKL is also
regulated by PGE2.
(20,28,58) Osteoblasts, stromal cells, and
ﬁbroblasts all express increased RANKL after treatment
with PGE2.
(20,28,58,59) This effect is primarily caused by
activation of the EP4 receptor, which activates the PKA
signaling pathway. Gain of EP4 function stimulated
RANKL expression, whereas loss of function prevents
RANKL expression in PGE2-treated cells.
(20) RANKL has
been shown to be expressed in chondrocytes, and our
laboratory recently has established that BMP-2 signaling
is a potent inducer of RANKL expression in chondro-
cytes.
(60) However, direct induction of RANKL by PGE2
has not been examined in a chondrocyte population. Al-
together, regulation of BMP-2 and RANKL by COX-2/
PGE2 is consistent with an early gene that regulates critical
subsequent steps including cell differentiation and subse-
quent remodeling.
The likely source of the mesenchymal precursor popu-
lation is the periosteum. Prior work from our laboratory
using a murine bone/periosteal cell transplant model
clearly established that periosteal cells undergo prolifera-
tion and subsequent chondrogenesis in response to in-
jury.
(25) In a murine model in which PGE2 was delivered to
the periosteal surface through an Alzet pump, periosteal
bone formation occurred in wildtype and EP1, EP2, and
EP3 knockout mice, but not in EP4-deﬁcient mice.
(26) This
suggests that the periosteal stem cell population is partic-
ularly responsive to EP4 signaling. For this reason, we
examined whether local delivery of an EP4 receptor ago-
nist could compensate for the reduced rate of fracture re-
pair observed in aged mice.
Local injection of an EP4 agonist to the fracture site of
aged mice compensated for the reduced fracture repair
observed with aging. Day 14 fractures were selected for
detailed analysis because this is the time point in which
fractures in young animals are completing the ﬁnal stages
of endochondral ossiﬁcation and only the ﬁnal vestiges of
hypertrophic cartilage remain. In contrast, aged mice con-
tinued to have abundant immature cartilage. Fractures re-
ceiving the EP4 agonist had a signiﬁcant reduction in both
immature and hypertrophic cartilage and more efﬁcient
completion of endochondral ossiﬁcation. This effect was
readily observed at day 14, when endochondral bone for-
mation is being completed in young mice and fracture union
is occurring. As a result, EP4 agonist–treated fractures in
aged mice had increased bone formation and developed a
histological phenotype that was similar to that observed in
young mice. Our gainof functionﬁndings are consistent with
prior work showing that EP4 knockout mice have delayed
endochondral bone formation and fracture healing.
(36)
A second ﬁnding observed in aged mice with fractures
treated with the EP4 agonist was that the total amount of
fracture callus was increased in mice treated with CP73 for
21 days. Unlike the observations at 14 days with cartilage
maturation, the increase in callus area and bone formation
occurred in comparison with both vehicle-treated young
and aged mice with fractures. One possible explanation for
these ﬁndings is that, in the later phases of fracture repair,
CP73 may have additional effects on the osteoblast popu-
lation that results in increased total bone formation and
callus area. Thus, once endochondral bone has formed,
EP4 may have an additional role in the proliferation, re-
cruitment, or retention of osteoblastic cell populations in-
volved in fracture repair. Prior work has established that
EP4 stimulates osteoblast differentiation and matrix pro-
duction.
(26,54,61,62) Furthermore, EP4 knockout mice were
observed to have reduced bone with aging and decreased
osteoblastogenesis, consistent with an important role in
bone formation.
(36)
ThisstudyfocusedontheexpressionpatternofCOX-2in
fractures, the reduction in COX-2 expression in fractures in
a model of aging, and the potential of COX-2/EP4 gain of
function to compensate for and accelerate fracture repair
in the setting of aging. The work did not address the issue
of whether an EP4 receptor agonist has the potential to
stimulate repair in young mice, and this remains an impor-
tant issue. The molecular events associated with nonunions
in young subjects are not understood and it is possible the
EP4 receptor gain of function may have a role in promoting
normal and delayed fracture repair in young individuals.
The experiments used only a single dose of the EP4
agonist, CP73. CP73 has previously been shown to restore
trabecular bone mass and strength in ovariectomized
rats.
(63,64) Based on the doses used in rats, we chose a daily
injection of 20 mg/kg/d, which represents the maximal ef-
fects in these animal models. Because the goal of these
experiments was to show the concept that a EP4 gain of
function can compensate for the reduced rate of fracture
healing observed in aged mice, experiments designed to
determine the relative potency of different concentrations
of CP73 were not completed. Similarly, we did not study
the relative potential of other factors, such as BMP-2 or
PTH, to compensate for reduced fracture healing in the
aging model. PTH and BMP-2 are important and perhaps
overlapping or integrated pathways that have been shown
to regulate bone repair.
(29,51,65–68) Similar to EP4, the PTH
receptor is a G-coupled protein receptor that activates the
protein kinase A signaling pathway.
(65) Whereas these
agents may have an important role in fractures in aging, the
current studies focused on the role of EP4 receptor sig-
naling. Future studies will need to determine the relative
effectiveness of these and other agents.
Altogether, the experiments showed that the impaired
fracture healing with aging involves essentially all stages
of the process and suggest that altered expression of early
genes involved in fracture repair affect the entire healing
cascade. These ﬁndings deﬁne COX-2/EP4 signaling as an
important potential therapeutic target to improve fracture
healing in the aging population.
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